Steve Thorne

Steve Thorne

Company: KaliVir Immunotherapeutics

Job title: Chief Scientific Officer


Using Oncolytic Viruses to Target TGF-β in the Tumor Microenvironment 3:15 pm

Directly targeting tumors using OVs to avoid systematic toxicity for better patient response Targeting the TGF-β receptors with oncolytic viruses for strong immune response Uncovering preclinical success using OVs to show clinical efficacy New Data!Read more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.